All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The torrid pace predicted for dealmaking going forward, as identified in the Reed Smith survey described in this issue, was reaffirmed in the fifth annual BDO Biotech Briefing, which found that M&A activity remains strong despite a tough third quarter for biotech stocks and IPOs. The briefing found that almost a quarter (23.6 percent) of companies included on the Nasdaq Biotechnology Index (NBI) have been involved in M&A transactions so far in 2015.